Frankfurt - Delayed Quote EUR

BridgeBio Pharma, Inc. (2CL.F)

27.97

-0.53

(-1.86%)

At close: January 10 at 4:16:03 PM GMT+1

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors

GlobeNewswire 3 days ago

BBIO
BridgeBio price target raised to $50 from $45 at Evercore ISI

Evercore ISI raised the firm’s price target on BridgeBio (BBIO) to $50 from $45 and keeps an Outperform rating on the shares following Attruby’s approval and management discussions. The firm is updating its Attruby model to reflect 100% probability of success from 95%, pricing of $244,000 per year, and the firm’s increasingly constructive view on Attruby’s label, which could help future differentiation, the analyst tells investors in a research note. Evercore thinks its model is still conservati

TipRanks 18 days ago

BBIO
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on positive results from the Phase 3 ATTRibute-CM study; final approval decision, typically consistent with the CHMP recommendation, is expected from the European Commission within the coming monthsAcoramidis, a near-complete (≥90%) stabilizer of transthyretin (TTR), was approved on November 22, 2024, by the U.S. Food and Drug Administration (FDA) as Attruby™ to reduce cardiovascu

GlobeNewswire 29 days ago

BBIO
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

SAVA and APLT tank on pipeline and regulatory setbacks.

Zacks last month

BBIO

APLT

SAVAW
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

Zacks last month

BBIO

PFE
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

Zacks last month

ALNY

BBIO

NVS
BridgeBio price target raised to $45 from $42 at BofA

BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the FDA approved its stabilizer acoramidis as Attruby for ATTR-CM. The news, arriving ahead of the November 29 PDUFA deadline, was “a win on many levels, marking the company’s evolution into a commercial entity with a label that is “best-case,” the analyst tells investors. ATTR-CM’s upside is “still underappreciated currently,” the analyst added. Published firs

TipRanks last month

BBIO
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.

Investor's Business Daily last month

NTLA

BBIO

PFE
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. The FDA approval is based on ATTRibute-CM Phase 3 study results, which showed that Attruby significantly reduced death and cardiovascular-related hospitalization and improved quality of life. Also Read: BridgeBio Pharma’s Acoramidis S

Benzinga last month

BBIO

PFE
FDA approves BridgeBio’s Attruby for ATTR-CM treatment

The approval triggers a $500m payment to BridgeBio under a royalty funding agreement.

Pharmaceutical Technology last month

BBIO
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes - Attruby demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date: - In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalizations (CVH)) durably

GlobeNewswire last month

BBIO
BridgeBio heart drug approved by FDA, setting up battle with Pfizer

BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved with a broad label that looks competitive to Pfizer's tafamidis.

BioPharma Dive last month

BBIO

PFE

ALNY
Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other biotech stocks. Biotechnology Stocks: Navigating Volatility Amid Market Fluctuations and Industry Growth Biotechnology stocks are among the most volatile in the market […]

Insider Monkey last month

BBIO
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions. ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis, an investigational small-molecule stabilizer of transthyretin (TTR) gene. Also Read: BridgeBio Pharma’s Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease The OL

Benzinga last month

BBIO

PFE
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically

One thing we could say about the analysts on BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) - they aren't optimistic, having...

Simply Wall St. last month

BBIO
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension- The continued curve separation of the composite endpoint of ACM and recurrent cardiovascular-related hospitalizations (CVH) emphasizes the importance of early intervention resulting in early and sustained clinical benefits, with acoramidi

GlobeNewswire last month

BBIO
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

- In Cohort 5 of PROPEL 2, daily oral treatment of infigratinib at 0.25mg/kg resulted in statistically significant and sustained increases in annualized height velocity (AHV), with a mean change from baseline of +2.50cm/year at Month 18 (P=0.001) - Data also presented at European Society of Paediatric Endocrinology on November 18th at 10 am GMT - To date, infigratinib has received Breakthrough Designation from the U.S. Food and Drug Administration for achondroplasia, as well as Orphan Drug Desig

GlobeNewswire last month

BBIO
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

BridgeBio Pharma ( NASDAQ:BBIO ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.73m (down 33% from 3Q...

Simply Wall St. last month

BBIO
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 16.50% and 54.21%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

BBIO
BridgeBio Pharma: Q3 Earnings Snapshot

PALO ALTO, Calif. AP) — BridgeBio Pharma Inc. BBIO) on Tuesday reported a loss of $162 million in its third quarter.

Associated Press Finance last month

BBIO

PANW

Performance Overview

Return	2CL.F	S&P 500
YTD	+6.55%	-1.35%
1-Year	-20.72%	+22.51%
3-Year	+111.89%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BridgeBio Pharma, Inc. (2CL.F)

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

BridgeBio price target raised to $50 from $45 at Evercore ISI

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

BridgeBio Stock Up on FDA Approval of Cardiovascular Drug

FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

BridgeBio price target raised to $45 from $42 at BofA

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BridgeBio heart drug approved by FDA, setting up battle with Pfizer

Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates

BridgeBio Pharma: Q3 Earnings Snapshot

Performance Overview